FDA Contradicts AAM's Generic Market Consolidation Argument

As the generic industry trade group warns shortages could emerge as number of manufacturers contracts, US FDA says many new firms gaining approvals and identifying facilities.

FDA entrance sign 2016

FDA may wind up hurting the generic industry's drug pricing narrative that deflation could force market consolidation and ultimately drug shortages.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership